Cystatin C Kidney Monitoring
TL;DR
Cystatin C (CysC) is a low-molecular-weight cysteine protease inhibitor produced at a constant rate by all nucleated cells. Unlike creatinine, it is not affected by muscle mass changes — making it the correct kidney function biomarker for anyone using creatine supplementation, undergoing GLP-1/retatrutide therapy, or at risk of sarcopenia. CKD-EPI 2021 race-free cystatin C equation (P30: 87–90%) and BIS2 combined equation (P30 >90%, misclassification 11.6%; recommended by KDIGO 2024) are the preferred estimators. Apple Watch eGFR is creatinine-based and is unreliable for Ben’s profile.
Why it matters for Vitals
Three reasons cystatin C is critical for Ben’s stack:
- Creatine supplementation — raises serum creatinine 15–30% via pharmacokinetic artifact; creatinine-based eGFR (including Apple Watch) reads 10–30 mL/min too low. Cystatin C is unaffected.
- Retatrutide-induced lean mass loss — less muscle → less creatinine production → creatinine falls even if GFR is stable or improving. Cystatin C is independent of muscle mass and gives the honest reading.
- Sarcopenia / aging — muscle mass decline causes creatinine-based eGFR to read falsely high. Cystatin C is protected from this artifact.
Bottom line: For anyone on creatine, GLP-1 therapy, or at risk of age-related muscle loss, cystatin C eGFR is the only reliable kidney function marker. Creatinine-based eGFR is misleading in both directions.
Key facts
What cystatin C is
- 13 kDa cysteine protease inhibitor produced by all nucleated cells
- Freely filtered by glomerulus, almost entirely reabsorbed by proximal tubule, catabolized (not secreted)
- Constant production rate: 0.124 ± 0.023 mg/min/1.73 m² in healthy adults PMID 16025834
- Non-renal clearance: ~22.3 mL/min/1.73 m² (~15% of total clearance at normal GFR) — why CysC is only mildly elevated in kidney failure compared to creatinine PMID 16025834
- Half-life: ~2 hours (secondary sources; primary radiolabeled study unverified)
Cystatin C vs creatinine comparison
| Scenario | Creatinine eGFR | Cystatin C eGFR | Preferred |
|---|---|---|---|
| Creatine supplementation | Falsely low (−10–30 mL/min) | Accurate | Cystatin C |
| Retatrutide/GLP-1 lean mass loss | Falsely high | Accurate | Cystatin C |
| Sarcopenia / aging | Falsely high | More accurate | Cystatin C |
| Stable muscle mass, normal weight | Accurate | Accurate | Either |
Reference ranges (cystatin C itself, mg/L)
| Age | Range | Median |
|---|---|---|
| <50 years | 0.53–0.92 | ~0.75 |
| ≥50 years | 0.58–1.02 | ~0.85–0.95 |
| 70s | — | ~1.04 |
| 80s | — | ~1.24 |
Cystatin C threshold for concern: >1.0 mg/L warrants investigation; >1.5 mg/L is a clinical alert.
CKD staging (cystatin C eGFR)
| Stage | eGFR (mL/min/1.73m²) | Description |
|---|---|---|
| G1 | ≥90 | Normal or high |
| G2 | 60–89 | Mildly decreased |
| G3a | 45–59 | Mildly to moderately decreased |
| G3b | 30–44 | Moderately to severely decreased |
| G4 | 15–29 | Severely decreased |
| G5 | <15 | Kidney failure |
eGFR Equations
CKD-EPI 2021 Race-Free Cystatin C Equation
Source: PMID 34554658 (NEJM 2021); recommended by PMID 38490803 (KDIGO 2024)
eGFR = 133 × (CysC/0.8)^α − 0.499 × (CysC/0.8)^1.328 × 0.996^age × 0.963 [if female]
Where α = −0.322 if CysC > 0.8 mg/L; −1.132 if CysC ≤ 0.8 mg/L; age ≥18 years.
P30 accuracy: 87–90% (external validation in Korean cohorts vs. iohexol-measured GFR). No race coefficient.
BIS2 Equation — Combined Creatinine + Cystatin C
Source: PMID 23027318 (Earley et al., 2012); recommended by PMID 38490803 (KDIGO 2024)
eGFR = 3839 × CysC^−0.739 × Creat^−0.547 × 0.963^age × 0.739 [if female]
(creatinine in mg/dL; cystatin C in mg/L; age ≥40)
- Misclassification rate: 11.6% (lowest among compared equations)
- P30 accuracy: >90% in octogenarian validation cohorts
- KDIGO 2024 recommends BIS2 as most accurate estimator when both markers are available
BIS2 caveat: BIS2 superiority is most established in older adults (≥70 years). For a young male on retatrutide with changing muscle mass, BIS2 adds value over CKD-EPI cystatin C alone when both markers are available, but the margin may be smaller than in elderly populations.
Practical priority for Ben: BIS2 > CKD-EPI cystatin C alone > creatinine-only eGFR. Apple Watch eGFR is not usable.
Non-GFR Determinants of Cystatin C
Cystatin C is not a perfect GFR surrogate. Multiple factors affect it independent of true GFR.
Factors that FALSE-ELEVATE cystatin C
| Factor | Magnitude | Evidence |
|---|---|---|
| Glucocorticoids (≥0.170 mg/kg/day prednisone equivalent) | +20–50% elevation | High PMID 31352865 |
| Hyperthyroidism | Significant elevation; normalize after treatment | High PMID 12675875 |
| Class II–III obesity | OR 2.82 for elevated CysC | Reported PMID 18374694 |
| Active HIV with viremia | Elevation vs. HIV-negative | Reported |
| Active inflammation/sepsis | Possible; conflicting | Low |
| Diabetes (hyperglycemia per se) | Independent association | Reported PMID 19119287 |
Factors that FALSE-REDUCE cystatin C
| Factor | Magnitude | Evidence |
|---|---|---|
| Hypothyroidism | Significant reduction; normalize after treatment | High PMID 12675875 |
| Advanced liver cirrhosis with ascites | Overestimates GFR by 10–20 mL/min | Reported |
Clinical implication: Thyroid status must be known before interpreting cystatin C. Glucocorticoid use makes cystatin C unreliable as a kidney marker.
GLP-1 / Retatrutide — No Direct Effect on Cystatin C
Evidence from retatrutide Phase 2 RCT PMID 40630318: eGFR changes tracked equivalently across creatinine-based, cystatin C-based, and combined equations. This confirms that eGFR changes with retatrutide reflect real hemodynamic/weight-loss effects, not marker-specific biases.
GLP-1/retatrutide does NOT affect cystatin C production or clearance directly. The kidney benefit seen in semaglutide SELECT trial PMID 38796653 is mediated via HbA1c, BP, and weight improvements.
Important: Retatrutide causes significant lean mass loss. Less muscle → less creatinine → creatinine falls even if GFR is stable. This makes creatinine-based eGFR appear better than it is. Cystatin C-based eGFR is protected from this confound.
Cystatin C and Cardiovascular Risk
Multiple cohorts (LIPID, LURIC, Heart and Soul, AGES-Reykjavik) and meta-analyses show higher cystatin C is associated with increased all-cause mortality (HR 1.87–3.6 per SD increase) and CV events independent of eGFR PMID 35179040.
However: Mendelian randomization studies refute a causal role. The association is confounded by low GFR itself, inflammation, and comorbidity burden.
Verdict: Cystatin C is a risk marker (not a causal risk factor) for CV events. It may improve CV risk stratification by providing a more accurate GFR estimate in muscle-mass-changing populations.
Serial Monitoring — Variability Limitation
Cystatin C has higher intra-individual biological variability than creatinine:
- Cystatin C CV: ~6–8%
- Creatinine CV: ~4–5%
This means cystatin C is better for snapshot assessment but worse for serial trajectory monitoring than creatinine. Small changes in eGFR over time may be noise.
Practical implication: For single measurements (snapshot risk assessment), cystatin C is superior for Ben’s profile. For trend monitoring, plot both creatinine eGFR and cystatin C eGFR; require concordant direction to call a real trend. Minimum 6-month intervals between tests to overcome noise.
Minimum detectable change: A >20% change in eGFR over 3–6 months is clinically meaningful in CKD literature. Smaller changes may be noise.
Lab Testing
| Parameter | Detail |
|---|---|
| Quest code | 94588 (Cystatin C + eGFR); CPT 82610 |
| LabCorp code | 121265 (Cystatin C + eGFR); CPT 82610 |
| LabCorp BIS2 code | 121022 |
| Self-pay range | ~130 |
| Fasting | Not required |
| Preferred when available | BIS2 (LabCorp 121022) |
Insurance may cover when there is a documented clinical indication (established CKD, diabetes, hypertension, or unreliable creatinine eGFR). For Ben (apparently healthy, creatine user), self-pay is viable at 130.
Vitals Coaching Zones
See Cystatin C Detection Model for full zone definitions, Apple Watch override logic, and monitoring frequency algorithm.
Summary:
| Zone | Cystatin C | eGFR | Action |
|---|---|---|---|
| 🟢 Green | <1.0 mg/L | ≥90 | Routine monitoring; retest at 6-month retatrutide follow-up |
| 🟡 Yellow | 1.0–1.5 mg/L OR | 60–89 | Hydration; minimize nephrotoxins; retest in 4–6 weeks; flag if on glucocorticoids or thyroid meds |
| 🔴 Red | >1.5 mg/L OR | <60 | Clinical review within 1–2 weeks; Apple Watch eGFR must NOT be used |
⚠️ Human sign-off required for any Red-zone finding. These are evidence-adapted coaching thresholds, not clinical practice guidelines.
Monitoring Frequency
| Context | Interval |
|---|---|
| Green zone | Every 6 months (aligned with quarterly retatrutide follow-ups) |
| Yellow zone | Every 4–6 weeks (retest); then every 3–4 months ongoing |
| Red zone | Within 2 weeks (clinical review) |
| Triggered by acute illness, dehydration, NSAID use | Within 2 weeks |
Related notes
Satellite / child notes:
- Cystatin C Detection Model — coaching zones, Apple Watch override logic, monitoring frequency algorithm, lab integration
Existing notes reused:
- Creatinine Artifact — Creatine Supplementation — mechanistic basis for why Apple Watch eGFR is unreliable; Creatine hub
- Muscle Health Biomarkers — cystatin C preferred over creatinine; Sarcopenia Index formula; IGF-1 and creatinine details
- Sarcopenia Detection — cystatin C in muscle health monitoring context; EWGSOP2 framework
- GLP-1 Body Composition — lean mass loss on GLP-1; connection to kidney biomarker interpretation
- Retatrutide — Ben’s GLP-1 agent; cystatin C eGFR as primary kidney metric
- GLP-1 Muscle Preservation — preservation evidence; connection to cystatin C as monitoring tool
Aspirational links:
- ~DEXA body composition — DEXA hub note not yet created; body composition hub should own DEXA reference
- ~Omega-3 Index — already planned in knowledge map
Key PMIDs
| PMID | Topic |
|---|---|
| 34554658 | CKD-EPI 2021 race-free cystatin C equation (NEJM) |
| 38490803 | KDIGO 2024 CKD guideline |
| 23027318 | BIS2 equation |
| 40630318 | Retatrutide Phase 2 eGFR comparison |
| 38796653 | Semaglutide SELECT trial kidney outcomes |
| 12675875 | Thyroid dysfunction effect on cystatin C |
| 16025834 | Non-renal clearance of cystatin C |
| 31352865 | Glucocorticoid effect on cystatin C production |
| 18374694 | Obesity and elevated cystatin C (NHANES III, OR 2.82) |
| 19119287 | Diabetes and cystatin C association |
| 35179040 | Cystatin C and CV mortality (LIPID cohort) |
| 10672373 | Reference ranges for plasma cystatin C (Finney et al. 2000) |